Stellar Biotech Announces First Quarter 2016 Corporate Update Conference Call

PORT HUENEME, CA--(Marketwired - Feb 4, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (NASDAQ: SBOT) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), will host its first quarter 2016 corporate update conference call and live webcast on Wednesday, February 10, 2016 at 1:30 PM ET (10:30 AM PT).

To listen to the live conference call, please dial 1-913-981-5510 and use the passcode 9642481. To join via the live webcast, please use the following link: https://www.webcaster4.com/Webcast/Page/1359/13282 .

Live Conference Call Information:
Date: Wednesday, February 10, 2016
Time: 1:30 PM ET / 10:30 AM PT
Conference call dial-in: 1-913-981-5510
Conference call passcode: 9642481
Webcast Link: https://www.webcaster4.com/Webcast/Page/1359/13282
Q&A Submission: Questions for management may be submitted via the chat feature of the live online webcast.

An archived replay version of the conference call will be available approximately two hours after the live call ends through Wednesday, February 24, 2016 at 11:59 PM Eastern Time by dialing (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) and entering passcode 9642481. The webcast replay will be available shortly after the conference call; to review visit the "Investors" section of the Stellar's Company website at: http://ir.stellarbiotechnologies.com/events-calendar.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Back to news